当前位置：
X-MOL 学术
›
Radiother. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): A randomised, phase III, trial
Radiotherapy and Oncology ( IF 4.9 ) Pub Date : 2020-01-01 , DOI: 10.1016/j.radonc.2019.10.014 Indrajit N Fernando 1 , Sarah J Bowden 2 , Kathryn Herring 2 , Cassandra L Brookes 3 , Ikhlaaq Ahmed 2 , Andrea Marshall 4 , Robert Grieve 5 , Mark Churn 6 , David Spooner 1 , Talaat N Latief 1 , Rajiv K Agrawal 7 , Adrian M Brunt 8 , Andrea Stevens 1 , Andrew Goodman 9 , Peter Canney 10 , Jill Bishop 11 , Diana Ritchie 10 , Janet Dunn 4 , Christopher J Poole 5 , Daniel W Rea 2 ,
Radiotherapy and Oncology ( IF 4.9 ) Pub Date : 2020-01-01 , DOI: 10.1016/j.radonc.2019.10.014 Indrajit N Fernando 1 , Sarah J Bowden 2 , Kathryn Herring 2 , Cassandra L Brookes 3 , Ikhlaaq Ahmed 2 , Andrea Marshall 4 , Robert Grieve 5 , Mark Churn 6 , David Spooner 1 , Talaat N Latief 1 , Rajiv K Agrawal 7 , Adrian M Brunt 8 , Andrea Stevens 1 , Andrew Goodman 9 , Peter Canney 10 , Jill Bishop 11 , Diana Ritchie 10 , Janet Dunn 4 , Christopher J Poole 5 , Daniel W Rea 2 ,
Affiliation
Highlights • SECRAB is the largest chemo-radiotherapy trial to date in early breast cancer.• SECRAB showed a positive therapeutic benefit of using adjuvant synchronous chemo-radiotherapy.• Synchronous chemo-radiotherapy should be used for ≤ 3 week radiotherapy schedules.• SECRAB results are applicable to patients having CMF or anthracycline-CMF schedules.• Overall survival outcome may increase for patients receiving synchronous anthracycline-CMF.
中文翻译：
早期乳腺癌患者的同步放化疗 (SECRAB)：一项随机 III 期试验
亮点 • SECRAB 是迄今为止规模最大的早期乳腺癌放化疗试验。• SECRAB 显示了使用辅助同步放化疗的积极治疗效果。• 同步放化疗应用于 ≤ 3 周的放疗计划。• SECRAB 结果适用于接受CMF 或蒽环类-CMF 治疗方案的患者。• 接受同步蒽环类-CMF 治疗的患者的总体生存结果可能会增加。
更新日期：2020-01-01
中文翻译：
早期乳腺癌患者的同步放化疗 (SECRAB)：一项随机 III 期试验
亮点 • SECRAB 是迄今为止规模最大的早期乳腺癌放化疗试验。• SECRAB 显示了使用辅助同步放化疗的积极治疗效果。• 同步放化疗应用于 ≤ 3 周的放疗计划。• SECRAB 结果适用于接受CMF 或蒽环类-CMF 治疗方案的患者。• 接受同步蒽环类-CMF 治疗的患者的总体生存结果可能会增加。
京公网安备 11010802027423号